GSK Boosts Stake In Theravance, An Apparent Nod To The Biotech's Respiratory Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline raises its stake in Relovair partner Theravance to 19% in a $129.4 million investment that extends the biopharma's cash runway.
You may also be interested in...
For Theravance, A Big Year Gets Off To A Strong Start
Theravance could soon have its first substantial revenue generator on the market, the COPD therapy Breo Ellipta partnered with GlaxoSmithKline. The launch of Breo is just one of several catalysts expected to unfold for the biotech in 2013.
Further Mixed Results For GSK/Theravance’s Relovair Have Investors Holding Breath
GSK and Theravance released preliminary results of two Phase III studies for their COPD drug Relovair that could serve to help differentiate the drug from Advair.
Relovair Data Raises Respiratory Stakes For GSK And Theravance
Mixed Phase III data results on GSK/Theravance’s once-daily follow-up to Advair raises the regulatory and commercial stakes for the drug, a crucial pipeline product for both companies